ReviewImmunoTargets and therapy2026
Comprehensive Review of Immunotherapy in Colorectal Cancer: From Mechanisms to Nursing Interventions.
Review in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a highly prevalent malignant tumor of the digestive tract worldwide, with significant regional variations in its epidemiological characteristics. Traditional treatments including surgery, chemotherapy, and radiotherapy have limited efficacy and substantial adverse events, which can no longer meet clinical needs. In recent years, immunotherapy has brought new breakthroughs for CRC by reshaping the tumor microenvironment (TME) and blocking tumor immune escape. This review systematically summarizes the core mechanisms and clinical applications of major immunotherapies such as immune checkpoint inhibitors (ICIs) and oncolytic viruses (OVs). We focus on individualized treatment selection for different molecular subtypes (pMMR/MSS vs. dMMR/MSI-H), biomarker screening, efficacy evaluation, drug resistance mechanisms, and countermeasures. We also discuss novel targets and biomarker optimization for precision therapy. In addition, given the unique immune-related adverse events, we introduce the CRC "SSEIE" nursing model and its value in whole-process management. This review integrates the latest advances in CRC immunotherapy and nursing interventions, providing a reference for optimizing clinical regimens, improving nursing quality, and enhancing patient prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.